Antisense drug discovery and development
T Yamamoto, M Nakatani, K Narukawa… - Future medicinal …, 2011 - Taylor & Francis
Numerous chemically modified oligonucleotides have been developed so far and show their
own unique chemical properties and pharmacodynamic/pharmacokinetic characteristics …
own unique chemical properties and pharmacodynamic/pharmacokinetic characteristics …
[PDF][PDF] Bridged nucleic acids: development, synthesis and properties
S Obika, SMA Rahman, A Fujisaka… - …, 2010 - triggered.stanford.clockss.org
Restricting the sugar moiety of a nucleic acid to a single conformation can be accomplished
by forming a bridge in the sugar. A large number of bridged nucleic acids with variable …
by forming a bridge in the sugar. A large number of bridged nucleic acids with variable …
Pharmacokinetic–pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense …
R Shimizu, M Kitade, T Kobayashi, SI Hori… - … of pharmacokinetics and …, 2015 - Springer
Second-generation antisense oligonucleotides (ASOs) demonstrate excellent biological
stability and in vitro/in vivo potency, and thus are considered to be attractive candidates for …
stability and in vitro/in vivo potency, and thus are considered to be attractive candidates for …
[PDF][PDF] Bridged nucleic acids (BNAs) as molecular tools
SK Kim, KD Linse, P Retes, P Castro… - Journal of Biochemistry …, 2015 - researchgate.net
There has been a growing interest in developing chemically modified nucleotides for
diagnostics or therapeutics. Among the list of the artificial nucleotides, bridged nucleic acids …
diagnostics or therapeutics. Among the list of the artificial nucleotides, bridged nucleic acids …
Synergistic Stabilization of Nucleic Acid Assembly by 2′-O,4′-C-Methylene-Bridged Nucleic Acid Modification and Additions of Comb-Type Cationic Copolymers
H Torigoe, A Maruyama, S Obika, T Imanishi… - Biochemistry, 2009 - ACS Publications
Stabilization of nucleic acid assemblies, such as duplex and triplex, is quite important for
their wide variety of potential applications. Various stabilization methods, including …
their wide variety of potential applications. Various stabilization methods, including …
Chemo-enzymatic synthesis of bicyclic 3′-azido-and 3′-amino-nucleosides
Conformationally locked 3′-azido-3′-deoxythymidine analogues of T, U, A and C
containing a 2′-O, 4′-C-methylene linked bicyclic furanose moiety has been efficiently …
containing a 2′-O, 4′-C-methylene linked bicyclic furanose moiety has been efficiently …
Synthesis of protected amino hexitol nucleosides as building blocks for oligonucleotide synthesis
S De, AM Jabgunde, RS Patil… - The Journal of …, 2018 - ACS Publications
A new synthesis protocol for the preparation of hitherto unknown 1′, 5′-anhydro-4′-
amino-trityl/MMTr hexitol nucleosides has been developed. Key steps in the synthesis of the …
amino-trityl/MMTr hexitol nucleosides has been developed. Key steps in the synthesis of the …
Bridged Nucleic Acids for Therapeutic Oligonucleotides
MA Islam, S Obika - Handbook of Chemical Biology of Nucleic Acids, 2022 - Springer
Recent developments in genetic technologies for genomic analysis, diagnostics, and
therapeutics have revolutionary effects on medical science. Oligonucleotide (ON) molecules …
therapeutics have revolutionary effects on medical science. Oligonucleotide (ON) molecules …
Chemical modification of triplex-forming oligonucleotide to promote pyrimidine motif triplex formation at physiological pH
H Torigoe, O Nakagawa, T Imanishi, S Obika, K Sasaki - Biochimie, 2012 - Elsevier
Extreme instability of pyrimidine motif triplex DNA at physiological pH severely limits its use
in wide variety of potential applications, such as artificial regulation of gene expression …
in wide variety of potential applications, such as artificial regulation of gene expression …
Exon skipping oligomer conjugates for muscular dystrophy
MA Passini, GJ Hanson - US Patent 11,000,600, 2021 - Google Patents
QHBNBYIJLYVZCF-FSINLKFRSA-N CC1= CN ([C@ H] 2CN (C) C [C@@ H](COP (= O)(N
(C) C) N3C [C@@ H](COP (= O)(N (C) C) N4C [C@@ H](COP (= O)(N (C) C) N5C [C …
(C) C) N3C [C@@ H](COP (= O)(N (C) C) N4C [C@@ H](COP (= O)(N (C) C) N5C [C …